REVOLUTION MEDICINES INC. - COMMON STOCK

39.40

30-May-25 13:45:00

15 minutes delayed

Stocks

+0.31

+0.81%

Today's range

37.95 - 40.19

ISIN

N/A

Source

NASDAQ

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

23 Oct 2024 03:00:49 By Nasdaq GlobeNewswire
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

21 Oct 2024 13:05:39 By Nasdaq GlobeNewswire
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

07 Oct 2024 06:00:01 By Nasdaq GlobeNewswire
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

07 Aug 2024 13:05:41 By Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

31 Jul 2024 13:05:11 By Nasdaq GlobeNewswire
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer

11 Jul 2024 09:00:53 By Nasdaq GlobeNewswire
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024

08 Jul 2024 13:05:00 By Nasdaq GlobeNewswire
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

05 Jun 2024 13:05:28 By Nasdaq GlobeNewswire
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress

08 May 2024 13:02:54 By Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

01 May 2024 13:05:56 By Nasdaq GlobeNewswire
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

09 Apr 2024 12:34:07 By Nasdaq GlobeNewswire
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

08 Apr 2024 08:36:55 By Nasdaq GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences

04 Apr 2024 13:05:04 By Nasdaq GlobeNewswire
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

28 Mar 2024 13:05:40 By Nasdaq GlobeNewswire
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

26 Feb 2024 13:05:50 By Nasdaq GlobeNewswire
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20 Feb 2024 13:05:47 By Nasdaq GlobeNewswire
Revolution Medicines to Participate in Upcoming Investor Conferences

01 Feb 2024 13:05:00 By Nasdaq GlobeNewswire
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

04 Jan 2024 04:00:08 By Nasdaq GlobeNewswire
Revolution Medicines Completes Acquisition of EQRx

09 Nov 2023 06:10:58 By Nasdaq GlobeNewswire
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

08 Nov 2023 08:30:46 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.